Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia

NACompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 3, 2014

Primary Completion Date

May 23, 2016

Study Completion Date

May 23, 2016

Conditions
Hyperlipidemia
Interventions
DRUG

Atorvastatin 20 mg

The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.

DRUG

Cholestyramine 8 g

The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.

DRUG

Omega-3 2g

The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.

DRUG

Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg

The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.

BEHAVIORAL

Lifestyle modification

The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.

Trial Locations (1)

03722

Division of Cardiology, Department of Internal Medicine,, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02942602 - Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia | Biotech Hunter | Biotech Hunter